Benjamin Besse
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 415
- Lung Cancer Diagnosis and Treatment 107
- Oncology 464
- Lung Cancer Research Studies 194
- Cancer Immunotherapy and Biomarkers 180
- Colorectal Cancer Treatments and Studies 87
- Co-authors
- Jean‐Charles Soria (119 shared papers)David Planchard (163 shared papers)Jordi Remón (83 shared papers)Roberto Ferrara (39 shared papers)Julien Mazières (66 shared papers)Laura Mezquita (108 shared papers)Caroline Caramella (74 shared papers)Lizza Hendriks (43 shared papers)
- Journals
- Annals of Oncology (134 papers)Journal of Clinical Oncology (131 papers)Journal of Thoracic Oncology (91 papers)European Journal of Cancer (33 papers)Lung Cancer (30 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Benjamin Besse
669 papers receiving 18.5k citations
Benjamin Besse's Hit Papers
Peers
Comparison fields: 5 of 148
- Oncology 12.2k
- Pulmonary and Respiratory Medicine 10.4k
- Cancer Research 3.8k
- Immunology 2.2k
- Molecular Biology 5.6k
Countries citing papers authored by Benjamin Besse
This map shows the geographic impact of Benjamin Besse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Besse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Besse more than expected).
Fields of papers citing papers by Benjamin Besse
This network shows the impact of papers produced by Benjamin Besse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Besse. The network helps show where Benjamin Besse may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Besse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 708 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Hit paper breakdown → | 2017 | 948 |
| 2 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 712 |
| 3 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial Hit paper breakdown → | 2016 | 612 |
| 4 | Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives Hit paper breakdown → | 2013 | 489 |
| 5 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial Hit paper breakdown → | 2017 | 487 |
| 6 | CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients Hit paper breakdown → | 2015 | 459 |
| 7 | 2010 | 357 | |
| 8 | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Hit paper breakdown → | 2021 | 321 |
| 9 | ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2019 | 269 |
| 10 | 2018 | 268 | |
| 11 | 2018 | 253 | |
| 12 | 2019 | 248 | |
| 13 | 2017 | 244 | |
| 14 | 2014 | 242 | |
| 15 | 2019 | 229 | |
| 16 | 2010 | 229 | |
| 17 | 2013 | 221 | |
| 18 | 2015 | 219 | |
| 19 | 2012 | 218 | |
| 20 | Tumour burden and efficacy of immune-checkpoint inhibitors Hit paper breakdown → | 2021 | 209 |
About Benjamin Besse
Benjamin Besse is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Epidemiology, having authored 708 papers that have together received 18.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (415 papers), Lung Cancer Research Studies (194 papers), Cancer Immunotherapy and Biomarkers (180 papers), Cancer Genomics and Diagnostics (128 papers), Lung Cancer Diagnosis and Treatment (107 papers), Colorectal Cancer Treatments and Studies (87 papers), Myasthenia Gravis and Thymoma (49 papers) and Cancer therapeutics and mechanisms (37 papers). The work is most often cited by research in Oncology (12.2k citations), Pulmonary and Respiratory Medicine (10.4k citations), Cancer Research (3.8k citations), Immunology (2.2k citations) and Molecular Biology (5.6k citations). Benjamin Besse has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Jean‐Charles Soria, David Planchard, Jordi Remón, Roberto Ferrara, Julien Mazières, Laura Mezquita, Caroline Caramella, Lizza Hendriks, Fabrice Barlési and Nathalie Chaput. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, European Journal of Cancer and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.